How Lenvima Targets Thyroid Cancer Cells
Lenvima (lenvatinib) treats thyroid cancer by blocking multiple enzymes called tyrosine kinases that drive tumor growth and spread. It inhibits vascular endothelial growth factor receptors (VEGFR1-3), which tumors use to build new blood vessels for nutrients and oxygen. Lenvima also targets fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, disrupting signals that make cancer cells multiply and survive.[1][2]
In thyroid cancer, especially radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), these pathways overactivate after standard treatments fail. By cutting off vascular supply and growth signals, Lenvima shrinks tumors or slows progression. Clinical trials showed it extended median progression-free survival to 18.3 months versus 3.6 months with placebo.[3]
Which Thyroid Cancers Does Lenvima Treat?
Lenvima is FDA-approved for:
- RAI-refractory differentiated thyroid cancer (DTC, including papillary and follicular types) in adults.[1]
- In combination with everolimus for advanced renal cell carcinoma, but not primary for thyroid.
- Advanced hepatocellular carcinoma, though thyroid remains its first approval (2015).[2]
It does not treat medullary thyroid cancer (MTC) or anaplastic types as monotherapy, though RET inhibition may benefit RET-mutated MTC off-label.[4]
How Is Lenvima Given for Thyroid Cancer?
Standard dose is 24 mg orally once daily, continuous until disease progression or intolerance. Doctors adjust for side effects like hypertension or proteinuria, often reducing to 20 mg, 14 mg, or 10 mg.[1][2] Treatment continues long-term; response rates hit 65% in trials, with some patients stable over 2 years.[3]
Common Side Effects and Management
Hypertension (68% of patients), diarrhea (59%), fatigue (59%), and decreased appetite (54%) occur most often. Serious risks include arterial thromboembolism, heart failure, and liver issues. Blood pressure monitoring and dose tweaks manage most cases; 75% complete 6 months of therapy.[1][3] Patients with thyroid cancer report hand-foot syndrome and weight loss as frequent complaints.
How Does Lenvima Compare to Sorafenib (Nexavar)?
Both are multikinase inhibitors for RAI-refractory DTC. Lenvima doubled progression-free survival (18.3 vs. 3.6 months placebo; sorafenib 10.8 months) and had higher response rates (65% vs. 12%). Lenvima causes more hypertension but less hand-foot skin reaction.[3][5] No head-to-head trial exists.
When Did Lenvima Get Approved and What's the Patent Status?
FDA approved February 2015 based on SELECT trial. U.S. patents expire around 2028-2034, with challenges from generics like MSN Labs. Exclusivity ended 2022; biosimilars unlikely soon due to small-molecule status. Check DrugPatentWatch.com for updates.6
[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206947s018lbl.pdf
[2]: https://www.lenvima.com/
[3]: https://www.nejm.org/doi/full/10.1056/NEJMoa1403292
[4]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327939/
[5]: https://pubmed.ncbi.nlm.nih.gov/26143923/